NanoEcho (NANECH) Q3 2025 earnings summary

Executive summary

• Achieved first commercial revenue through a system sale to Lund University, marking a key milestone toward commercialization and clinical validation.

• Focused on clinical adaptation and preparation for a Proof of Concept study, with system improvements based on clinical feedback.

• Maintained a strong position in a growing global market for colorectal cancer diagnostics, with a patented, innovative system targeting unmet needs.

Financial highlights

• Q3 2025 net sales reached 488 TSEK, compared to 0 TSEK in Q3 2024, reflecting the first system sale.

• Net loss after tax for Q3 2025 was -2,037 TSEK, improved from -2,963 TSEK in Q3 2024.

• Cash flow from operations for Q3 2025 was -3,656 TSEK, similar to -3,681 TSEK in Q3 2024.

• Cash and cash equivalents at period end were 4,881 TSEK, down from 11,690 TSEK a year earlier.

• Solid equity ratio of 88% as of September 30, 2025.

Outlook and guidance

• Preparing for a Proof of Concept clinical study in the first half of 2026, with ongoing system enhancements.

• Plans to submit documentation for market approval by 2028, contingent on securing necessary capital.

• Strategic focus on commercialization, market acceptance, and early revenue generation.